Evidence map›Paper›PMID 41298345›Full record

ArticleCell death & disease2025

SKA3-mediated hypoxia tolerance and metabolic reprogramming promote liver metastasis in lung adenocarcinoma.

Zedong Sun, Minmin Zhou, Ningdan Song, Can Wang, Mingrui Liu, Simian He, Feifan Ji, Jiayu Chen, Lin Xu, Xiufen Zheng and 1 more

Abstract read
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zedong Sun *Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Minmin Zhou *Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Cancer Institute of Jiangsu Province, Nanjing, PR China.
Ningdan Song *Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Can Wang *Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Mingrui LiuDepartment of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Simian HeDepartment of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Feifan JiDepartment of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Jiayu ChenDepartment of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China.
Lin XuJiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China. xulin_83@hotmail.com.ORCID http://orcid.org/0000-0001-6490-1471
Xiufen ZhengKey Laboratory of Emergency and Trauma of Ministry of Education, Department of Pharmacy and Engineering Research Center of Tropical Medicine Innovation and Transformation, The First Affiliated Hospital, Hainan Medical University, Haikou, PR China. hyyfy4440@muhn.edu.cn.
Binhui RenJiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China. renbinhui@jszlyy.com.cn.ORCID http://orcid.org/0000-0001-6741-3887

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82002435National Natural Science Foundation of China (National Science Foundation of China) 82172624
6 · The paper itself

Abstract

Late-stage lung adenocarcinoma (LUAD) frequently results in distant metastasis, with liver metastasis indicating the poorest prognosis. To successfully colonize the liver, metastatic LUAD cells must overcome its relatively hypoxic microenvironment. This study explores the metabolic adaptations that facilitate LUAD liver metastasis, identifying Spindle and Kinetochore Associated Protein 3 (SKA3) as a critical mediator. Under hypoxic conditions, SKA3 expression is significantly upregulated, driving glucose metabolic reprogramming in LUAD cells to enable survival within the liver's hypoxic niche. Mechanistically, SKA3 competitively binds to prolyl hydroxylase domain-containing protein 2 (PHD2), disrupting its interaction with hypoxia-inducible factor 1-alpha (HIF-1α). Consequently, stabilized HIF-1α further enhances glycolytic enzyme transcription, amplifying glycolysis and enabling adaptation to liver hypoxia. Furthermore, hypoxia upregulates the E3 ubiquitin ligase MDM2, promoting p53 ubiquitination and degradation, thereby relieving p53-mediated repression of SKA3 and further reinforcing the SKA3/HIF-1α axis. Interestingly, HIF-1α directly binds to the hypoxia response element (HRE) in the SKA3 promoter, creating a positive feedback loop to maintain high SKA3 expression. Thus, SKA3-mediated metabolic reprogramming significantly contributes to LUAD cells colonization and proliferation in the liver. Finally, our findings demonstrated that the SKA3/HIF-1α axis was critical for establishing hypoxia tolerance in LUAD cells, underscoring its potential as a therapeutic target for treating liver metastasis in LUAD.

Indexed as

Adenocarcinoma of LungCell Cycle ProteinsLiver NeoplasmsLung NeoplasmsMicrotubule-Associated ProteinsAnimalsCell HypoxiaCell Line, TumorGene Expression Regulation, NeoplasticGlycolysisHumansHypoxia-Inducible Factor 1, alpha SubunitHypoxia-Inducible Factor-Proline DioxygenasesMetabolic ReprogrammingMiceMice, NudeCell Cycle ProteinsEGLN3 protein, humanHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitHypoxia-Inducible Factor-Proline DioxygenasesMicrotubule-Associated ProteinsProto-Oncogene Proteins c-mdm2Tumor Suppressor Protein p53

Identifiers

PMID41298345
PMCPMC12827483

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.